Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab Plus Lenvatinib in Advanced/Metastatic Clear Cell Renal Cell Carcinoma
NCT06035224Phase 2Active, not recruiting
- Sponsor
- Renji Hospital
- Start
- Aug 2023
- Primary completion
- Jan 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab in clear cell renal cell carcinoma (ccRCC), sponsored by Renji Hospital. Primary endpoint: Objective Response Rate up to 2 years. Started Aug 2023; status: active, not recruiting.
02
Drugs
cadonilimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT06035224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06035224.